Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of$ 0.24 per share. This compares to loss of $0.53 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 337.50%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of$ 0.37 per share when it actually produced earnings of $0.23, delivering a surprise of 162.16%.Over the ...